Avalo Therapeutics, Inc. (NasdaqCM: AVTX)
Health Care · Biotechnology · US
$13.65
+1.64% today · -8.8% 1Y
Avalo Therapeutics, Inc. (NasdaqCM: AVTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $732.05M and employs 33 people.
Over the last twelve months the share price has lost 8.8%, trading between 12.51 and 24.27.
Tweenvest scores Avalo Therapeutics, Inc. across four factors: quality 35/100, value 90/100, growth 0/100. Its strongest factor is value.
AVTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $732.05M
- Revenue (TTM)
- $59.00K
- P/E
- —
- EPS
- -4.18
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- $24.27
- 52-week low
- $12.51
- Avg volume (3M)
- —
- Shares outstanding
- 53.63M
- Employees
- 33
- Next earnings
- —
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
- ISIN
- US05338F3064
- Founded
- 2011
- Listed since
- Oct 14, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| JS Link, Inc.KOSDAQ: A127120 | $743.20M | ₩28,750.00 | -1.54% |
| HanchorBio Inc.TWSE: 7827 | $739.81M | NT$169.00 | +1.20% |
| Solid Biosciences Inc.NasdaqGS: SLDB | $736.64M | $6.87 | +0.29% |
| 4D Molecular Therapeutics, Inc.NasdaqGS: FDMT | $736.41M | $13.33 | +4.96% |
| Design Therapeutics, Inc.NasdaqGS: DSGN | $729.08M | $11.65 | +1.39% |
| ChemPartner PharmaTech Co.,Ltd.SZSE: 300149 | $713.97M | CN¥9.47 | -4.34% |
| Prime Medicine, Inc.NasdaqGM: PRME | $709.84M | $3.99 | +11.45% |
| Pharming Group N.V.ENXTAM: PHARM | $694.55M | €0.88 | +3.72% |
Figures last refreshed Oct 11, 2026.